- Home
- LITB vs INTS Comparison
LITB vs INTS Comparison
Compare LITB & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITB
- INTS
- Stock Information
- Founded
- LITB 2007
- INTS 2012
- Country
- LITB Singapore
- INTS United States
- Employees
- LITB N/A
- INTS N/A
- Industry
- LITB Catalog/Specialty Distribution
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- LITB Consumer Discretionary
- INTS Health Care
- Exchange
- LITB Nasdaq
- INTS Nasdaq
- Market Cap
- LITB N/A
- INTS 35.3M
- IPO Year
- LITB N/A
- INTS 2023
- Fundamental
- Price
- LITB $1.00
- INTS $2.33
- Analyst Decision
- LITB
- INTS Strong Buy
- Analyst Count
- LITB 0
- INTS 3
- Target Price
- LITB N/A
- INTS $8.50
- AVG Volume (30 Days)
- LITB 21.6K
- INTS 18.1K
- Earning Date
- LITB 03-24-2025
- INTS 03-21-2025
- Dividend Yield
- LITB N/A
- INTS N/A
- EPS Growth
- LITB N/A
- INTS N/A
- EPS
- LITB N/A
- INTS N/A
- Revenue
- LITB $333,093,000.00
- INTS N/A
- Revenue This Year
- LITB N/A
- INTS N/A
- Revenue Next Year
- LITB N/A
- INTS N/A
- P/E Ratio
- LITB N/A
- INTS N/A
- Revenue Growth
- LITB N/A
- INTS N/A
- 52 Week Low
- LITB $0.91
- INTS $1.50
- 52 Week High
- LITB $6.00
- INTS $5.78
- Technical
- Relative Strength Index (RSI)
- LITB 41.05
- INTS 53.36
- Support Level
- LITB $0.92
- INTS $2.17
- Resistance Level
- LITB $1.05
- INTS $2.43
- Average True Range (ATR)
- LITB 0.05
- INTS 0.20
- MACD
- LITB 0.01
- INTS 0.01
- Stochastic Oscillator
- LITB 61.54
- INTS 73.08
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.